These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 32886279)

  • 41. Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial.
    Rambaldi A; Grassi A; Masciulli A; Boschini C; Micò MC; Busca A; Bruno B; Cavattoni I; Santarone S; Raimondi R; Montanari M; Milone G; Chiusolo P; Pastore D; Guidi S; Patriarca F; Risitano AM; Saporiti G; Pini M; Terruzzi E; Arcese W; Marotta G; Carella AM; Nagler A; Russo D; Corradini P; Alessandrino EP; Torelli GF; Scimè R; Mordini N; Oldani E; Marfisi RM; Bacigalupo A; Bosi A
    Lancet Oncol; 2015 Nov; 16(15):1525-1536. PubMed ID: 26429297
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen.
    Aggarwal C; Gupta S; Vaughan WP; Saylors GB; Salzman DE; Katz RO; Nance AG; Tilden AB; Carabasi MH
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):770-7. PubMed ID: 16785066
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A modified busulfan and cyclophosphamide preparative regimen for allogeneic transplantation in myeloid malignancies.
    Cai X; Wei J; He Y; Yang D; Jiang E; Huang Y; Han M; Feng S
    Int J Clin Pharm; 2015 Feb; 37(1):44-52. PubMed ID: 25432692
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An evaluation of busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation.
    Takamatsu Y; Ogata K; Yamauchi K; Hara S; Kamimura T; Hayashi S; Suzumiya J; Tamura K
    Jpn J Clin Oncol; 2005 Jul; 35(7):400-3. PubMed ID: 15976066
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes.
    Rezvani AR; McCune JS; Storer BE; Batchelder A; Kida A; Deeg HJ; McDonald GB
    Biol Blood Marrow Transplant; 2013 Jul; 19(7):1033-9. PubMed ID: 23583825
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reduced-intensity conditioning allogeneic blood stem cell transplantation with fludarabine and oral busulfan with or without pharmacokinetically targeted busulfan dosing in patients with myeloid leukemia ineligible for conventional conditioning.
    Martino R; Pérez-Simón JA; Moreno E; Queraltó JM; Caballero D; Mateos M; Sureda A; Cañizo C; Brunet S; Briones J; Vazquez L; Clopés A; San Miguel JF; Sierra J
    Biol Blood Marrow Transplant; 2005 Jun; 11(6):437-47. PubMed ID: 15931632
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.
    de Lima M; Couriel D; Thall PF; Wang X; Madden T; Jones R; Shpall EJ; Shahjahan M; Pierre B; Giralt S; Korbling M; Russell JA; Champlin RE; Andersson BS
    Blood; 2004 Aug; 104(3):857-64. PubMed ID: 15073038
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study.
    Andersson BS; Madden T; Tran HT; Hu WW; Blume KG; Chow DS; Champlin RE; Vaughan WP
    Biol Blood Marrow Transplant; 2000; 6(5A):548-54. PubMed ID: 11071260
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality.
    McCune JS; Batchelder A; Deeg HJ; Gooley T; Cole S; Phillips B; Schoch HG; McDonald GB
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):853-62. PubMed ID: 17580264
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells.
    Bornhauser M; Storer B; Slattery JT; Appelbaum FR; Deeg HJ; Hansen J; Martin PJ; McDonald GB; Nichols WG; Radich J; Woolfrey A; Jenke A; Schleyer E; Thiede C; Ehninger G; Anasetti C
    Blood; 2003 Aug; 102(3):820-6. PubMed ID: 12676781
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation.
    Ansari M; Théoret Y; Rezgui MA; Peters C; Mezziani S; Desjean C; Vachon MF; Champagne MA; Duval M; Krajinovic M; Bittencourt H;
    Ther Drug Monit; 2014 Feb; 36(1):93-9. PubMed ID: 24061446
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation--a retrospective analysis.
    Schetelig J; Bornhäuser M; Kiehl M; Schwerdtfeger R; Kröger N; Runde V; Zabelina T; Held TK; Thiede C; Fauser AA; Beelen D; Zander A; Ehninger G; Siegert W;
    Bone Marrow Transplant; 2004 Mar; 33(5):483-90. PubMed ID: 14716342
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients.
    Kröger N; Zabelina T; Krüger W; Renges H; Stute N; Kabisch H; Jaburg N; Löliger C; Krüll A; Zander AR
    Bone Marrow Transplant; 2001 Feb; 27(4):349-54. PubMed ID: 11313663
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen.
    Beri R; Chunduri S; Sweiss K; Peace DJ; Mactal-Haaf C; Dobogai LC; Shord S; Quigley JG; Chen YH; Mahmud N; Rondelli D
    Bone Marrow Transplant; 2010 Feb; 45(2):249-53. PubMed ID: 19543331
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients.
    Andersson BS; Thall PF; Valdez BC; Milton DR; Al-Atrash G; Chen J; Gulbis A; Chu D; Martinez C; Parmar S; Popat U; Nieto Y; Kebriaei P; Alousi A; de Lima M; Rondon G; Meng QH; Myers A; Kawedia J; Worth LL; Fernandez-Vina M; Madden T; Shpall EJ; Jones RB; Champlin RE
    Bone Marrow Transplant; 2017 Apr; 52(4):580-587. PubMed ID: 27991894
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study.
    Nguyen L; Leger F; Lennon S; Puozzo C
    Cancer Chemother Pharmacol; 2006 Jan; 57(2):191-8. PubMed ID: 16133536
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adverse Effects of Busulfan Plus Cyclophosphamide versus Busulfan Plus Fludarabine as Conditioning Regimens for Allogeneic Bone Marrow Transplantation.
    Mehdizadeh M; Parkhideh S; Salari S; Hajifathali A; Rezvani H; Mabani M
    Asian Pac J Cancer Prev; 2021 May; 22(5):1639-1644. PubMed ID: 34048196
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oral busulfan pharmacokinetics and engraftment in children with Hurler syndrome and other inherited metabolic storage diseases undergoing hematopoietic cell transplantation.
    Jacobson P; Park JJ; DeFor TE; Thrall M; Abel S; Krivit W; Peters C
    Bone Marrow Transplant; 2001 Apr; 27(8):855-61. PubMed ID: 11477444
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reduced-toxicity conditioning therapy with allogeneic stem cell transplantation for acute leukemia.
    Andersson BS; de Lima M; Thall PF; Madden T; Russell JA; Champlin RE
    Curr Opin Oncol; 2009 Jun; 21 Suppl 1(Suppl 1):S11-5. PubMed ID: 19561406
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission.
    Kunter G; Perkins JB; Pidala J; Nishihori T; Kharfan-Dabaja MA; Field T; Fernandez H; Perez L; Locke F; Ayala E; Tomblyn M; Ochoa-Bayona JL; Betts B; Nieder M; Anasetti C
    Bone Marrow Transplant; 2014 Jan; 49(1):11-6. PubMed ID: 23995098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.